PL3006457T3 - Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości - Google Patents
Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowościInfo
- Publication number
- PL3006457T3 PL3006457T3 PL15191391T PL15191391T PL3006457T3 PL 3006457 T3 PL3006457 T3 PL 3006457T3 PL 15191391 T PL15191391 T PL 15191391T PL 15191391 T PL15191391 T PL 15191391T PL 3006457 T3 PL3006457 T3 PL 3006457T3
- Authority
- PL
- Poland
- Prior art keywords
- pes
- pseudomonas exotoxins
- mutated
- reduced antigenicity
- mutated pseudomonas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70379805P | 2005-07-29 | 2005-07-29 | |
| EP10179539.1A EP2332970B1 (en) | 2005-07-29 | 2006-07-25 | Mutated pseudomonas exotoxins with reduced antigenicity |
| EP06788523A EP1910407B1 (en) | 2005-07-29 | 2006-07-25 | Mutated pseudomonas exotoxins with reduced antigenicity |
| EP15191391.0A EP3006457B1 (en) | 2005-07-29 | 2006-07-25 | Mutated pseudomonas exotoxins with reduced antigenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3006457T3 true PL3006457T3 (pl) | 2018-05-30 |
Family
ID=37709138
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15191395T PL3006458T3 (pl) | 2005-07-29 | 2006-07-25 | Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości |
| PL15191388T PL3006456T3 (pl) | 2005-07-29 | 2006-07-25 | Zmutowane egzotoksyny pseudomonas o zmniejszonej antygenowości |
| PL15191391T PL3006457T3 (pl) | 2005-07-29 | 2006-07-25 | Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15191395T PL3006458T3 (pl) | 2005-07-29 | 2006-07-25 | Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości |
| PL15191388T PL3006456T3 (pl) | 2005-07-29 | 2006-07-25 | Zmutowane egzotoksyny pseudomonas o zmniejszonej antygenowości |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8907060B2 (pl) |
| EP (6) | EP3006458B1 (pl) |
| AT (1) | ATE524489T1 (pl) |
| AU (1) | AU2006275865B2 (pl) |
| CA (2) | CA2616987C (pl) |
| ES (6) | ES2564092T3 (pl) |
| PL (3) | PL3006458T3 (pl) |
| WO (1) | WO2007016150A2 (pl) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7989322B2 (en) | 2007-02-07 | 2011-08-02 | Micron Technology, Inc. | Methods of forming transistors |
| WO2008109005A2 (en) * | 2007-03-02 | 2008-09-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers |
| ES2642516T3 (es) | 2007-09-04 | 2017-11-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Supresiones en el dominio II de la exotoxina A de Pseudomonas que reducen la toxicidad no específica |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| EP2475398B1 (en) * | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Improved pseudomonas exotoxin a with reduced immunogenicity |
| WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
| EP3797847A1 (en) | 2010-07-30 | 2021-03-31 | Medlmmune, LLC | Purified active polypeptides or immunoconjugates |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CN105541978B (zh) | 2010-09-15 | 2019-12-13 | 兰德尔·J·米斯尼 | 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法 |
| CN103596985B (zh) | 2011-04-19 | 2016-06-08 | 美国政府(由卫生和人类服务部的部长所代表) | 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途 |
| RU2600067C2 (ru) | 2011-05-06 | 2016-10-20 | Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез | Рекомбинантный иммунотоксин, нацеленный на мезотелин |
| CN103748107B (zh) * | 2011-06-09 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| WO2013039916A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| EP2755993B1 (en) | 2011-09-16 | 2017-11-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| PL397167A1 (pl) | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| SG11201407972RA (en) | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| WO2014031476A1 (en) | 2012-08-21 | 2014-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| JP6307085B2 (ja) | 2012-09-27 | 2018-04-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ | メソテリン抗体および強力な抗腫瘍活性を惹起するための方法 |
| CA2884431A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
| JP6553515B2 (ja) | 2012-12-20 | 2019-07-31 | メディミューン，エルエルシー | 免疫複合体の製造方法 |
| EP3038641B1 (en) | 2013-10-06 | 2019-04-17 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Modified pseudomonas exotoxin a |
| WO2015054691A2 (en) | 2013-10-11 | 2015-04-16 | The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services | Tem8 antibodies and their use |
| WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| WO2015120058A2 (en) | 2014-02-05 | 2015-08-13 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
| CA2948346C (en) | 2014-05-07 | 2023-06-27 | Applied Molecular Transport Llc | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| JP6811706B2 (ja) | 2014-07-31 | 2021-01-13 | ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー | Ｅｐｈａ４に対するヒトモノクローナル抗体及びそれらの使用 |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| CN108473575B (zh) | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | 抗-bcma多肽和蛋白质 |
| WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| CA3031559A1 (en) | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
| US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| WO2018213612A1 (en) | 2017-05-18 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin polypeptides and proteins |
| WO2018213064A1 (en) | 2017-05-19 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfer2 for cancer immunotherapy |
| CA3066953A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | Human monoclonal antibodies specific for cd33 and methods of their use |
| WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
| US11795235B2 (en) | 2017-09-18 | 2023-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotoxins with albumin binding domain |
| EP4316586A3 (en) | 2018-03-08 | 2024-05-08 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| US11939377B2 (en) | 2018-07-12 | 2024-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured CD22-specific monoclonal antibody and uses thereof |
| EP3833684A1 (en) | 2018-08-08 | 2021-06-16 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
| BR112021009001A8 (pt) | 2018-11-07 | 2021-10-26 | Applied Molecular Transport Inc | Veículos derivados de cholix para administração oral de carga útil heteróloga |
| CN113490510A (zh) | 2019-01-08 | 2021-10-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体 |
| AU2020212534A1 (en) | 2019-01-22 | 2021-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| CA3142833A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
| CA3150859A1 (en) | 2019-08-16 | 2021-02-25 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
| JP2022552875A (ja) | 2019-10-22 | 2022-12-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 多様な固形腫瘍を処置するためのｂ７ｈ３（ｃｄ２７６）を標的とする高親和性ナノボディ |
| WO2021097289A1 (en) | 2019-11-15 | 2021-05-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pegylated recombinant immunotoxins |
| US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
| CN116583539A (zh) | 2020-12-22 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体或其抗原结合片段的复合物及医药用途 |
| WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
| CN117500831A (zh) | 2021-06-09 | 2024-02-02 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体 |
| WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
| EP4448566A1 (en) | 2021-12-17 | 2024-10-23 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors |
| WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
| WO2024104584A1 (en) | 2022-11-17 | 2024-05-23 | University Of Cape Town | Deimmunized pseudomonas exotoxin a |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5621078A (en) * | 1989-03-22 | 1997-04-15 | Merck & Co., Inc. | Modified pseudomonas exotoxin PE40 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| ATE182175T1 (de) | 1990-05-11 | 1999-07-15 | Us Health | Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2129514A1 (en) | 1992-03-12 | 1993-09-16 | M. Amin Khan | Controlled released acth containing microspheres |
| AU675440B2 (en) * | 1992-06-18 | 1997-02-06 | United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant (pseudomonas) exotoxin with increased activity |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
| US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| AU7718696A (en) | 1995-10-27 | 1997-05-15 | Merck & Co., Inc. | Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines |
| DE69729389D1 (de) * | 1996-11-06 | 2004-07-08 | Nasa | Protease-aktivierbare pseudomonas exotoxin-a-ähnliche proproteine |
| US6296843B1 (en) | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| EP1180123B1 (en) * | 1999-05-27 | 2008-07-16 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
| WO2001034645A2 (en) | 1999-11-11 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Mutated il-13 molecules and their uses |
| EP1330766A2 (en) * | 2000-07-10 | 2003-07-30 | Xencor | Method for designing protein libraries with altered immunogenicity |
| ZA200305980B (en) * | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
| US7355012B2 (en) * | 2001-09-26 | 2008-04-08 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells |
| WO2003039600A1 (en) | 2001-11-09 | 2003-05-15 | Neopharm, Inc. | Selective treatment of il-13 expressing tumors |
| US7982011B2 (en) | 2003-11-25 | 2011-07-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
| WO2009014650A2 (en) * | 2007-07-20 | 2009-01-29 | The General Hospital Corporation | Recombinant vibrio cholerae exotoxins |
| ES2642516T3 (es) * | 2007-09-04 | 2017-11-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Supresiones en el dominio II de la exotoxina A de Pseudomonas que reducen la toxicidad no específica |
| WO2010111282A1 (en) * | 2009-03-24 | 2010-09-30 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
| WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| EP2475398B1 (en) * | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Improved pseudomonas exotoxin a with reduced immunogenicity |
| EP2576620A1 (en) * | 2010-05-26 | 2013-04-10 | Regents Of The University Of Minnesota | Single -chain variable fragment anti-cd133 antibodies and uses thereof |
| CN103748107B (zh) * | 2011-06-09 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a |
-
2006
- 2006-07-25 AT AT06788523T patent/ATE524489T1/de not_active IP Right Cessation
- 2006-07-25 EP EP15191395.1A patent/EP3006458B1/en active Active
- 2006-07-25 ES ES10179539.1T patent/ES2564092T3/es active Active
- 2006-07-25 EP EP10179520.1A patent/EP2311854B1/en active Active
- 2006-07-25 EP EP06788523A patent/EP1910407B1/en active Active
- 2006-07-25 ES ES10179520T patent/ES2410783T3/es active Active
- 2006-07-25 PL PL15191395T patent/PL3006458T3/pl unknown
- 2006-07-25 ES ES15191388T patent/ES2702650T3/es active Active
- 2006-07-25 CA CA2616987A patent/CA2616987C/en active Active
- 2006-07-25 EP EP10179539.1A patent/EP2332970B1/en active Active
- 2006-07-25 AU AU2006275865A patent/AU2006275865B2/en active Active
- 2006-07-25 EP EP15191391.0A patent/EP3006457B1/en active Active
- 2006-07-25 WO PCT/US2006/028986 patent/WO2007016150A2/en active Application Filing
- 2006-07-25 ES ES06788523T patent/ES2372537T3/es active Active
- 2006-07-25 ES ES15191391.0T patent/ES2659039T3/es active Active
- 2006-07-25 US US11/997,202 patent/US8907060B2/en active Active
- 2006-07-25 PL PL15191388T patent/PL3006456T3/pl unknown
- 2006-07-25 CA CA2941466A patent/CA2941466C/en active Active
- 2006-07-25 PL PL15191391T patent/PL3006457T3/pl unknown
- 2006-07-25 EP EP15191388.6A patent/EP3006456B1/en active Active
- 2006-07-25 ES ES15191395.1T patent/ES2660026T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2941466A1 (en) | 2007-02-08 |
| EP3006457A1 (en) | 2016-04-13 |
| WO2007016150A3 (en) | 2007-08-09 |
| ES2660026T3 (es) | 2018-03-20 |
| US8907060B2 (en) | 2014-12-09 |
| EP2311854B1 (en) | 2013-04-17 |
| WO2007016150A2 (en) | 2007-02-08 |
| ES2659039T3 (es) | 2018-03-13 |
| EP2332970A2 (en) | 2011-06-15 |
| CA2616987C (en) | 2016-10-11 |
| EP3006456A1 (en) | 2016-04-13 |
| EP2311854A1 (en) | 2011-04-20 |
| CA2616987A1 (en) | 2007-02-08 |
| US20090142341A1 (en) | 2009-06-04 |
| PL3006458T3 (pl) | 2018-05-30 |
| EP1910407A2 (en) | 2008-04-16 |
| EP3006457B1 (en) | 2017-11-22 |
| EP3006458A1 (en) | 2016-04-13 |
| AU2006275865A1 (en) | 2007-02-08 |
| AU2006275865B2 (en) | 2012-06-28 |
| EP2332970A3 (en) | 2011-09-14 |
| CA2941466C (en) | 2019-12-03 |
| ATE524489T1 (de) | 2011-09-15 |
| EP3006456B1 (en) | 2018-09-19 |
| ES2702650T3 (es) | 2019-03-04 |
| ES2564092T3 (es) | 2016-03-17 |
| ES2410783T3 (es) | 2013-07-03 |
| EP3006458B1 (en) | 2017-11-22 |
| EP1910407B1 (en) | 2011-09-14 |
| PL3006456T3 (pl) | 2019-05-31 |
| ES2372537T3 (es) | 2012-01-23 |
| EP2332970B1 (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3006457T3 (pl) | Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości | |
| HUS1700028I1 (hu) | Antitestek a Clostridium difficile toxinok ellen és azok felhasználásai | |
| HK1109636A1 (en) | Human antibodies and proteins | |
| PH12015501848A1 (en) | Binding agents | |
| WO2008121615A3 (en) | Antibody formulation | |
| EP2570425A3 (en) | Deletions in domain II of Pseudomonas exotoxin A that reduce non-specific toxicity | |
| WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
| DE602006021296D1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
| MY174493A (en) | Binding agents | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| NZ592432A (en) | Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) | |
| MX2010010776A (es) | Fusiones y conjugados de farmaco. | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| WO2016172551A3 (en) | Methods of identifying bacteria comprising binding polypeptides | |
| WO2007045019A3 (en) | Polyoleosins | |
| MX2009008754A (es) | Anticuerpos novedosos contra igf-1r. | |
| WO2008126065A3 (fr) | Polynucléotides et polypeptides impliqués dans le paludisme gestationnel, et applications biologiques | |
| MX2009011851A (es) | Plasmidos de dna que tienen expresion y estabilidad mejoradas. | |
| WO2006000753A3 (en) | Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer | |
| WO2006136892A3 (de) | Neuartige cherlasky - fusionsproteine enthalten antikorperbindeproteine oder ihre regionen | |
| WO2006123122A3 (en) | Psk- i and its modulators for the treatment/diagnosis of cancer | |
| UA103306C2 (en) | Normal;heading 1;heading 2;heading 3;HUMAN C-FMS ANTIGEN BINDING PROTEINS | |
| WO2012122125A3 (en) | Compositions and methods targeting force generation in kinesin |